SymBio Pharmaceuticals Limited
4582.TJPXHealthcareMedical - Pharmaceuticals
Latest quote
¥63.00
−¥2.00 · -3.08%
Aug 24, 3:30 PM JST
4582.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteSymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Fuminori Yoshida
- Listed since
- Oct 20, 2011
- Employees
- 91
Market position
52-week range
Current ¥63.00
¥62.00¥229
- Open
- ¥63.00
- Previous close
- ¥65.00
- Volume
- 0
- 0× average
- Average volume
- 832.68K
- Average daily volume
- Market cap
- 3.47B JPY
- Beta
- 0.53
- Market reference 1
- 50-day average
- ¥69.78
- -9.72% below average
- 200-day average
- ¥92.345
- -31.78% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.62B JPY
- EV / EBITDA
- -0.79×
- Earnings yield
- -105.69%
- Free cash flow yield
- -101.25%
Profitability & efficiency
- Return on equity
- -375.48%
- Return on assets
- -123.50%
- Return on invested capital
- -136.24%
Financial health
- Current ratio
- 2.96×
Earnings
- Latest EPS result
- -15
EPS: actual versus estimate
Recent quarterly results
ActualEstimate
Estimates unavailableRevenue: actual versus estimate
Recent quarterly results
ActualEstimate
Estimates unavailable4582.T peers
Continue in GoAI
Research 4582.Tresearch.disclaimer